A 2021 collaboration between Japan’s Takeda (TYO: 4502) and US-based BridGene Biosciences has successfully reached the primary objective of identifying a second novel target for neurodegenerative disorders. This achievement was made possible through the use of BridGene’s chemoproteomics platform, which is designed to discover and develop small molecules for undruggable targets. As a result of this milestone, BridGene will receive a payment from Takeda, as per their agreement which includes a total of up to five drug discovery programs.
BridGene’s Chemoproteomics Platform and Its Applications
BridGene’s technology stands out for its ability to identify disease-driving proteins and the targets that small-molecule drug candidates bind to within live cells. This capability is crucial in the development of new therapeutics for neurodegenerative disorders, which have historically been challenging to address with conventional drug discovery methods.
Implications for Drug Discovery and Development
The success of this collaboration highlights the potential of BridGene’s chemoproteomics platform in advancing the field of neurodegenerative disease research. The identification of new targets opens up new avenues for the development of effective treatments, offering hope for patients suffering from these debilitating conditions.-Fineline Info & Tech
